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Abstract
Background: The importance of the lung parenchyma in the pathophysiology of asthma has previously been
demonstrated. Considering that nitric oxide synthases (NOS) and arginases compete for the same substrate, it is
worthwhile to elucidate the effects of complex NOS-arginase dysfunction in the pathophysiology of asthma,
particularly, related to distal lung tissue. We evaluated the effects of arginase and iNOS inhibition on distal lung
mechanics and oxidative stress pathway activation in a model of chronic pulmonary allergic inflammation in guinea
pigs.
Methods: Guinea pigs were exposed to repeated ovalbumin inhalations (twice a week for 4 weeks). The animals
received 1400 W (an iNOS-specific inhibitor) for 4 days beginning at the last inhalation. Afterwards, the animals
were anesthetized and exsanguinated; then, a slice of the distal lung was evaluated by oscillatory mechanics, and
an arginase inhibitor (nor-NOHA) or vehicle was infused in a Krebs solution bath. Tissue resistance (Rt) and
elastance (Et) were assessed before and after ovalbumin challenge (0.1%), and lung strips were submitted to
histopathological studies.
Results: Ovalbumin-exposed animals presented an increase in the maximal Rt and Et responses after antigen
challenge (p<0.001), in the number of iNOS positive cells (p<0.001) and in the expression of arginase 2, 8-
isoprostane and NF-kB (p<0.001) in distal lung tissue. The 1400 W administration reduced all these responses
(p<0.001) in alveolar septa. Ovalbumin-exposed animals that received nor-NOHA had a reduction of Rt, Et after
antigen challenge, iNOS positive cells and 8-isoprostane and NF-kB (p<0.001) in lung tissue. The activity of arginase
2 was reduced only in the groups treated with nor-NOHA (p <0.05). There was a reduction of 8-isoprostane
expression in OVA-NOR-W compared to OVA-NOR (p<0.001).
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Conclusions: In this experimental model, increased arginase content and iNOS-positive cells were associated with
the constriction of distal lung parenchyma. This functional alteration may be due to a high expression of
8-isoprostane, which had a procontractile effect. The mechanism involved in this response is likely related to the
modulation of NF-kB expression, which contributed to the activation of the arginase and iNOS pathways. The
association of both inhibitors potentiated the reduction of 8-isoprostane expression in this animal model.
Keywords: Lung parenchyma, Arginase, iNOS, Nitric oxide, Guinea-pig, nor-NOHA, Oxidative stress
Background
Asthma is a disease of both the airways and, as recently
addressed, the alveolar parenchyma. Some studies have
demonstrated the presence of inflammation and the re-
modeling of lung parenchyma in asthma, both in humans
and in experimental models, showing the relevance of dis-
tal lung tissue responses in total pulmonary resistance and
the effects of inflammatory mediators in peripheral lung
changes [1-9].
Nitric oxide (NO) is an important endogenous modu-
lator of airway and distal lung constriction, generated by
a family of NO synthase (NOS) isoforms. Studies in macro-
phages have indicated that under conditions of low L-
arginine availability, iNOS not only produces NO via its
oxygenase moiety, but its reductase moiety also synthesizes
superoxide anions, leading to the efficient formation of
peroxynitrite [10]. Subsequently, isoprostane generation
may result from lipid peroxidation induced by pero-
xynitrite formation. PGF2α represents the main member of
the isoprostane family, which members are biochemical
markers of oxidative stress and are produced through the
peroxidation of arachidonic acid [10-12].
Airway inflammation is accompanied by a marked
upregulation of iNOS expression, particularly in airway
epithelium [13], that has been associated with the activa-
tion of nuclear factor-kB (NF-κB) that play critical roles
in inflammation, immunity, cell proliferation, differenti-
ation and survival [14]. Further studies showed that NF-
κB is activated in the lung tissue of animal models of
allergic airway inflammation [15] and of patients with
asthma [16], specifically within airway epithelium, and it
is known that NF-κB activity can be affected by reactive
oxygen species (ROS) as well as reactive nitrogen species
(RNS) [17].
Arginases, which convert L-arginine into L-ornithine
and urea, are key enzymes of the urea cycle in the liver
(arginase 1) but are also expressed in cells and tissues
that lack a complete urea cycle, for example, arginase 2
expression in the lung [18].
Que et al. [19] demonstrated the expression of argi-
nase in the bronchial epithelium and in peribronchial
connective tissue fibroblasts. In addition, Meurs et al.
[18] showed that arginase appears to modulate the tone
of airway smooth muscle and potentiates methacholine-
induced airway constriction. Arginase accomplishes this
by competing the common substrate L-arginine away
from epithelial cNOS to diminish agonist-induced NO
production. Arginases and NOS compete for the bio-
availability of the same substrate, L-arginine, and are in-
volved indirectly in the regulation of NO synthesis [20].
Several powerful drugs have been used to investigate the
role of arginase in the pathophysiology of asthma, includ-
ing nor-NOHA (Nω-hydroxy-nor-Larginine), which is one
of the most potent inhibitors of arginase [21]. Meurs et al.
[22], studying in vitro tracheal ring of sensitized guinea
pigs, demonstrated that treatment with nor-NOHA re-
duced hyperresponsiveness to methacholine, and this ef-
fect was reversed by treatment with L-NAME.
Previously, we had used guinea pigs with chronic aller-
gic inflammation treated with a false substrate for all
NOS (L-NAME) and a specific iNOS inhibitor (1400 W)
to demonstrate that all NOS constitutive isoforms re-
duced lung responsiveness and inflammatory response
and protected against extracellular matrix remodeling.
Moreover, NO derived from iNOS activation contributes
to increased lung responsiveness, inflammatory cells re-
cruitment and extracellular matrix remodeling both in
airways and distal lung parenchyma [2,3,5-7].
Considering these complex interactions, we hypothesis
that, increased arginase activity 2 also plays a key role in
the pathophysiology of chronic asthma. In order to clar-
ify this statement we evaluated the expression and activ-
ity of arginase 2 as well by treatment with a specific
inhibitor of arginase (Nu-hydroxy-or L-arginine: nor-
NOHA) attenuates mechanical oscillatory responses and
oxidative stress of lung tissue in a distal model chronic
allergic pulmonary inflammation.
Methods
Male guinea pigs received humane care in compliance with
the “Guide for the care and use of laboratory animals”
(NIH publication 85–23, revised 1985), and experiments
described in this study were previously approved by the In-
stitutional Review Board of the University of São Paulo.
Induction of chronic pulmonary allergic inflammation
Male Hartley guinea pigs weighing 300–400 g were
placed in a plexiglass box (30 × 15 × 20 cm) coupled to
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an ultrasonic nebulizer (Soniclear, São Paulo, Brazil). A
solution of ovalbumin (OVA, Grade V, Sigma Chemical
Co., Saint Louis, MO, USA) diluted in 0.9% NaCl (nor-
mal saline) was prepared. For four weeks, the animals
received seven inhalations of increasing concentrations
of OVA (1~5 mg/mL) to counteract tolerance (Figure 1).
Control animals received aerosolized normal saline (SAL
group). The solution was continuously aerosolized into
the environment until respiratory distress occurred, as
previously described [4,6,23]. The observer who made the
decision to withdraw the guinea pig from the inhalation
box was blinded to the treatment status of the animal.
1400W administration
1400 W (Tocris Bioscience, Ellisville, MO, USA) (a spe-
cific and highly selective iNOS-inhibitor) was given ip for
four days at 2 mg/kg/animal/day (OVA-W group), begin-
ning 30 minutes before the 7th inhalation of either ovalbu-
min or normal saline. This approach was chosen based on
previous data [6,24,25]. As high doses of 1400 W (50 mg/
kg ip) can cause toxic effects, we chose a lower dose with
previously demonstrated proven therapeutic efficacy in
experimental models [7,25].
nor-NOHA administration
Nor-NOHA (Nω-hydroxy-nor-Larginine, Caymam Chem-
ical, Ellsworth Road Ann Arbor, MI, USA) is considered
one of the most potent inhibitors of arginase, as previously
described [22]. At the beginning of the protocol nor-
NOHA (10 μM) was added to the Krebs bath and after 40
minutes we performed OVA (0.1%) challenge. Afterwards,
mechanical evaluation was done.
Experimental groups
The animals were randomly divided into the following
experimental groups (n = 6 for each group):
a) Inhalations with sterile saline 0.9% (SAL group);
b) Inhalations with ovalbumin solution (OVA group);
c) Inhalations with ovalbumin solution and treatment
with nor-NOHA in the bath (OVA-NOR group);
d) Inhalations with ovalbumin and treatment with
1400 W (ip) (OVA-W group);
e) Inhalations with ovalbumin solution and 1400 W (ip)
and nor-NOHA in the bath (OVA-NOR-W group).
Oscillatory mechanics measurements
Seventy-two hours after the 7th inhalation, the animals
were anesthetized with thiopental (50 mg/Kg (ip),
tracheostomized, and exsanguinated after thoracotomy.
Heart and lungs were excised en bloc, and the lungs
were infused with Krebs solution (in mM: NaCl, 118;
KCl, 4.5; NaHCO3, 25.5; CaCl2, 2.5; MgSO4, 1.2; KH2PO4,
1.2; glucose 10; all from Sigma Chemical). Sagittal slices of
both lungs (defined herein as total lung) were covered
with Optimum Cutting Temperature (OCT) compound
(Reichert-Jung, Heidelberg, Germany) and cooled in
liquid nitrogen for subsequent histopathological stud-
ies. Subpleural parenchyma strips of the lower lobes
(10 mm × 2 mm × 2 mm) were cut, and the resting
length (Lr) and wet weight (W0) of each strip were
measured. Metal clips were glued to either end of the tis-
sue strips with cyanoacrylate. Steel wires (0.5-mm diam-
eter) were attached to the clips; one side was connected to
a force transducer (model 404A; Cambridge Technologies,
Ontario, Canada), and the other side was connected to a
1st 2nd                  3rd                       4th
1 mg/mL 2.5 mg/mL 5mg/mL
Protocol for chronic pulmonary allergic inflammation
Oscillatory
Mechanical
Evaluation
Week
OVA solution
1stInhalations 2nd 3rd 4th
72 h
5th 6th 7th
1400 treatment 
2mg/Kg i.p.
24h
s
nor-NOHA (10 µM) 
Figure 1 Timeline of the experimental protocol. The guinea pigs underwent 7 inhalations (2 per week with 2- to 3-day intervals over 4 weeks)
with aerosols of normal saline or ovalbumin solution and increasing doses of antigen. For the 1st through the 4th inhalations, the dose used was
1 mg/mL of ovalbumin (2 weeks). In the 5th and 6th inhalations (3rd week), the animals inhaled 2.5 mg/mL of ovalbumin, and for the 7th
inhalation (beginning in the 4th week) 5 mg/mL of antigen was used. Treatment with 1400W started 30 minutes before the 7th inhalation and
was given daily until the oscillatory mechanics assessment. The solution of ovalbumin or normal saline was continuously aerosolized for 15
minutes or until respiratory distress occurred. Seventy-two hours after the 7th inhalation, the animals were anesthetized, exsanguinated, and their
lungs were removed for oscillatory mechanics measurement. Nor-NOHA (10 μM) was infused in the bath during the evaluation of
oscillatory mechanics.
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servo-controlled lever arm (model 300B; Cambridge Tech-
nologies). The lever arm was capable of peak-to-peak
length excursions of 8 mm and length resolutions of 1 μm.
It was connected to a function generator (model 3030; BK
Precision, Chicago, IL, USA), which controlled the fre-
quency, amplitude, and waveform of the oscillation.
The resting tension (T) was set by the movement of a
screw thumb wheel system, which effected slow vertical
displacements of the force transducer. Length and force
signals were converted from analog to digital with an
analog-to-digital converter and recorded by a compatible
computer. The strips were preconditioned three times
by slowly cycling tension from 0 to 2 g. After the third
cycle, they were fixed at 1 g [8] and maintained in an
organ bath containing aerated Krebs solution (95% of O2,
5% of CO2), which was changed every 15 minutes for 50
min to allow stress relaxation. The frequency of oscillation
was 1 Hz and the amplitude was 2.5% Lr [8]. Baseline
measurements of tissue resistance (Rt) and elastance (Et)
were obtained for 5 min, and then the maximal responses
of R and E were collected 10 min after a specific antigen
challenge with OVA (0.1%) in the bath [26]. The R and E
were estimated by the recursive least-squares algorithm to
the equation of motion [27].
T ¼ EΔlþ R Δl=Δtð Þ þ K ð1Þ
where T is tension, l is length, Δl/Δt is the length change
per unit of time, and K is a constant reflecting resting ten-
sion. The results were standardized for strip size. The un-
stressed cross-sectional area (A0) of the strip was obtained
from the formula:
A0 cm2
  ¼ W0= p x Lrð Þ ð2Þ
where p is the mass density of the tissue taken as 1.06 g/
cm3, W0 is the wet weight in grams, and Lr is the resting
length in centimeters. The values of R and E were multi-
plied by Lr/A0. We analyzed the percentage of increase
in resistance (%R) and elastance (%E) in relation to the
baseline [8]. Afterwards, the strips were fixed in 10%
formalin for 48 (hours) and embedded in paraffin for
histological analysis.
Morphometric analysis
The homogeneity of the strip samples was assured by
measuring the fractional area of tissue constituents with
the point-counting method [3,28,29] using a 100-point
grid with a known area (62,500 μm at 400× magnifica-
tion) attached to the ocular of the microscope. We mea-
sured the fractional area of bronchial wall (BW), blood
vessel wall (BVW), and alveolar wall (AW) as the num-
ber of points that fell in either BW, BVW or AW divided
by the total number of points that fell in the strip tissue.
Measurements were performed in 10 fields per slide at
400× magnification. We have calculated the mean values
for each animal. The morphometric analysis was performed
by two authors blinded to the experimental groups. The
variability of these measurements observed was 1% (coeffi-
cient of variation).
Measurement of iNOS positive cells
The total lung slices covered with OCT and cooled in li-
quid nitrogen were used for the detection of iNOS posi-
tive cells. The cryostat sections (Leica CM1850; Leica,
Nosfloch, Germany) were mounted on glass slides pre-
coated with aminopropyltriethoxysilane (Sigma Chemical
Co.) and fixed in chloroform-acetone (Merck, Rio de
Janeiro, Brazil) vol/vol for 10 minutes at room temperature.
Immunohistochemistry analysis was performed as previ-
ously described [6]. The sections were then incubated for
30 minutes at room temperature with a blocking solution
containing normal mouse serum (Dako Corp., Carpinteria,
CA, USA).
Monoclonal antisera raised in mouse against iNOS
(IgG2a - iNOS/NOS Type II - N32020 - BD Transduc-
tion Laboratories, San Diego, CA, USA) [6,7,30] were
used as the primary antisera (incubation overnight at
room temperature, 1:5 dilution in Tris buffer). After
three 5-minute washes in tris-buffered saline (TBS), the
sections were incubated with a secondary antibody
(LSAB+AP Link Universal, Dako Corp.) for 30 minutes
at 37°C in a humid chamber. The slides were given three
more 5-minute washes in TBS and were coverslipped
with pre-diluted (for 30 minutes) alkaline phosphatase
(LSAB + AP - Streptavidin AP - Dako Corp.). This was
followed by incubation with the substrate Fast Red TR
(Sigma Chemical Co.) for 6 minutes and light hema-
toxylin counterstaining for 1 minute. Ten fields were
analyzed per lung at a magnification of 1000× in an op-
tical microscope (104 μm2). The iNOS positive cells
were expressed as number of cells/104 μm2 [6,7].
Evaluation of NF-kB expression
The immunohistochemistry analysis was carried out
using biotin-streptavidin peroxidase. Histological sections
3 μm thick were made on silanized slides (3-Aminopropyl-
trietoxy-silane-Sigma) and the protocol described below
was followed. The slides were dewaxed, hydrated and the
endogenous peroxidase was blocked with hydrogen perox-
ide (3% H2O2) 10V 7 times for 5 minutes each, after which
the slides were washed with water and PBS. Antigen re-
trieval was performed in a pressure cooker (Pascal) for 1
minute at 125°C with citrate buffer pH: 6.0. After blocking,
the primary NF-kB antibody (cod. SC-109, Santa Cruz
Biotechnology, USA, CA), was diluted in BSA 1:50, applied
to the slides and incubated overnight. The slides were then
washed in PBS and incubated with secondary antibody
(1 hour) and complex (30 min) by ABCKit Vectastain
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(Vector Elite PK-6101 (anti-Rabbit) in an oven at 37°C.
After this step, the slides were washed in PBS and the anti-
body staining visualized through the addition of 3.3
chromogen diaminobenzidine (DAB - Dako K 3466). The
slides were washed thoroughly with tap water and counter-
stained with Harris hematoxylin (Merck, Darmstadt,
Germany). The slides were then washed in water,
dehydrated, cleared and mounted with Entellan resin
(Merck, Darmstadt, Germany). The NF-kB expression
was evaluated under ×400 magnification with an Image-
Pro Plus 4.5 v Image Analysis System [6,7], and the results
were obtained as a relationship between the quantity of
NF-kB expression in a specific frame and the total area of
the frame expressed as a percentage.
Evaluation of PGF2α expression
Immunohistochemical staining was performed using an
antibody against anti-8-iso-PGF2α (Oxford Biomedical
Research, Rochester Hills, MI, USA) at a 1:500 dilution.
The sections were deparaffinized and washed 7 times for
5 minutes with H2O210V 3% to inhibit endogenous per-
oxidase activity. After washes in PBS and water, the anti-
gen retrieval was performed with trypsin for 20 minutes.
Afterwards, 3 washes in PBS were performed for 3 minutes
each. The sections were incubated with anti-8-epi-PGF2
diluted in BSA overnight. After washes in PBS, ABCKit
Vectastain (Vector Elite PK-6105, Burlingame, CA) was
used as the secondary antibody and 3,3 Diaminobenzidine
(DAB) (Sigma Chemical Co) was used as the chromogen.
The sections were counterstained with Harris hematoxylin
(Merck) [31]. The PGF2α content was evaluated as de-
scribed in the section: Evaluation of NF-kB expression.
Arginase 2 expression
The arginase 2 antibody was evaluated with biotin-
streptavidin peroxidase. Histological sections 3 μm thick
were made on silanized (3-Aminopropyl-trietoxy-silane-
Sigma) slides. The sections were deparaffinized and hy-
drated, and the endogenous peroxidase was then blocked
with 3% hydrogen peroxide (H2O2) 7 times for 5 minutes
each, followed by washes with water and PBS. After
blocking, a primary antibody against arginase 2 (cod.
18357, Santa Cruz Biotechnology, USA, CA) was diluted
in BSA at 1:120 and incubated on the slides overnight.
The sections were then washed in PBS and incubated with
the secondary antibody (1 hour) and complex (30 min)
using ABCKit Vectastain Vector Elite PK-6105 (anti-Goat)
in a 37 degree oven. After this step, the sections were
washed in PBS and visualized with 3.3 chromogen
diaminobenzidine (DAB - Dako K 3466). The sections
were then washed thoroughly with tap water and counter-
stained with Harris hematoxylin (Merck, Darmstadt,
Germany). Finally, the sections were washed in water,
dehydrated, cleared and mounted with Entellan resin for
microscopy (Merck, Darmstadt, Germany). The arginase
content was evaluated as described in the section: Evalu-
ation of NF-kB expression.
Arginase 2 activity
After extraction, samples were immediately frozen in li-
quid nitrogen and stored at −80°C until homogenization.
Subpleural parenchyma strips were homogenized in an
extraction buffer (20 mM Tris (pH 7.4), 2 uM phenyl-
methanesulfonylfluoride (PMSF)) with a Polytron PTA
20S generator (model PT 10/35, Brinkmann Instruments,
Inc., Westbury, NY, USA) operated at maximum speed for
30 sec. The extracts were centrifuged at 15,000 g, 4°C, for
30 min to remove insoluble material. Protein concentra-
tions of the supernatants were determined by the Bradford
assay. QuantiChrom™ Arginase Assay Kit (DARG-200,
Bioassay Systems, Hayward, CA, USA) was used to assess
the activity of arginase. In short, 40 μl of homogenate was
plated into a 96-well plate and 10 μl of 5× substrate buffer
(4 vol of Arginine Buffer and 1 vol of the Mn Solution,
supplied in the kit) subsequently added. The controls
consisted of 40 μl of homogenate without substrate buffer
5×. The plate was incubated at 37°C for 2 hours. To stop
the reaction, 200 μl of urea reagent, supplied in the kit,
was added to each well and also 10 μl of 5× substrate
buffer to control samples. Plate was incubated for 60 mi-
nutes at room temperature. The reading was performed at
430 nm and the activity of arginase 2 was calculated by
measuring the reaction rate. One unit (U) of arginase
converts 1 umol of L-arginine to ornithine and urea per
minute at pH 9.5 and 37°C. The specific activity was
then expressed in terms of activity per milligram of pro-
tein (mU/mg).
Data analysis
Values were expressed as medians and percentiles and
graphics were performed as “Box plot”. The data were ex-
amined using Kruskal-Wallis non-parametric analysis of
variance. Multiple comparisons were made using Dunn’s
test. A p value < 0.05 was considered significant [32]. We
also obtained a Spearman correlation coefficient (R) to as-
sess the associations of the Rt scores with the NF-kB,
iNOS, isoprostane, PGF2α and arginase 2 expression. A
p value < 0.05 was considered significant [32].
Results
Values were expressed as medians and percentiles
[Median (25-75%)]
Inhibition of iNOS or Arginase 2 attenuates oscillatory
mechanics in sensitized animals
The ovalbumin-exposed animals (OVA group) presented
an increase in the %Rt [85.0 (69.6-144.0)] and %Et [63.6
(62.1-111.8)] after OVA challenge relative to the saline-
exposed ones (SAL group) (%Rt: [9.0 (3.5-18.0)] and %Et:
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[5.7 (1.3-11.1)] (p<0.001 for all comparisons). In the sensi-
tized animals, the nor-NOHA group (OVA-NOR group)
had lower %Rt [23.2 (4.5-35.8)] and %Et [18.2 (4.8-25.7)]
than the ovalbumin-exposed (OVA group) or the vehicle-
treated animals (p<0.001). The 1400 W administration in
ovalbumin-exposed animals (OVA-W group) reduced the
%Rt [43.1 (17.0-70.8)] and %Et [33.8 (11.6-57.1)] com-
pared to ovalbumin-exposed (OVA group) and vehicle-
treated animals (p<0.001). In sensitized GP, nor-NOHA
and 1400 W administration in ovalbumin-exposed ani-
mals (OVA-NOR-W group) reduced the %Rt [41.0 (31.5-
67.0)] and %Et [32.4 (16.4-50.9)] below values observed in
the OVA group (p<0.001). However, there were no differ-
ences between the OVA-NOR and OVA-NOR-W groups
(Figure 2 A and B).
Inhibition of iNOS or Arginase 2 attenuates arginase 2
expression and activity, the number of iNOS positive cells
and NF-kB expression
There was an increase in the arginase 2 expression
(Figure 3) in the ovalbumin-exposed animals (OVA
group) compared to the saline-exposed ones (SAL group)
[16.0 (13.7-22.7)] and [8.2 (1.8-13.4) %, respectively,
p<0.001]. The ovalbumin-exposed animals that received
nor-NOHA (OVA-NOR) [10.2 (6.2-13.4) %] and the
ovalbumin-exposed animals that received 1400W treat-
ment and nor-NOHA (OVA-NOR-W) [5.1 (2.4-10.3) %]
had lower arginase expression than the ovalbumin-
exposed animals (OVA group) (p<0.001). The ovalbumin-
exposed animals that received 1400W treatment and
nor-NOHA (OVA-NOR-W group) had lower arginase
expression in lung tissue than the OVA-W animals [12.8
(6.7-16.0) %, p<0.001]. However, there were no differ-
ences between the OVA-NOR and OVA-NOR-W groups.
There was an increase in arginase 2 activity (Figure 4)
in ovalbumin-exposed animals (OVA group) relative to
the saline-exposed animals (SAL group) [8.8 (7.0-10.8)
mU/mg] and [4.9 (4.7-5.2) mU/mg] respectively,
p<0.001). The ovalbumin-exposed animals that received
nor-NOHA (OVA-NOR) had lower arginase 2 activity
[3.6 (3.3-4.9) mU/mg] than the ovalbumin exposed
animals (OVA group) (p<0.05). The ovalbumin-exposed
animals that received both 1400W treatment and nor-
NOHA (OVA-NOR-W group) had lower arginase ex-
pression in lung tissue than the OVA-W animals [3.4
(2.4-4.3) mU/mg] and [8.6 (4.4-11.5) mU/mg, respect-
ively p<0.05]. Nevertheless, there were no differences be-
tween the OVA-NOR and OVA-NOR-W groups.
The ovalbumin-exposed animals (OVA group) showed
an increase in the number of iNOS positive cells (Figure 5)
in the alveolar septum [29.8 (19.3-49.2) cells/104 μm2]
compared to the animals exposed to saline (SAL group)
[6.4 (3.8-9.2) cells/104 μm2]. The ovalbumin-exposed ani-
mals that received nor-NOHA (OVA-NOR) showed a
lower number of iNOS positive cells [9.1 (6.1-14.7) cells/
104μm2] than the ovalbumin exposed ones (OVA group)
(p<0.001. The ovalbumin-exposed animals that received
1400 W and nor-NOHA (OVA-NOR-W group) had a
lower amount of iNOS positive cells in their lung tissue
than the OVA-W animals [11.7 (9.0-15.1)] and [27.5
(17.8-37.8) cells/104 μm2, respectively p<0.001]. However,
there were no differences between the OVA-NOR and
OVA-NOR-W groups.
Ovalbumin-exposed animals (OVA group) showed an
increase in NF-kB expression (Figure 6) in the alveolar
septum [14.8 (13.3-16.3) %] compared to the animals
exposed to saline (SAL group) [5.5 (4.5-7.5) %]. The
ovalbumin-exposed animals that received nor-NOHA
(OVA-NOR) showed less NF-kB expression [6.8 (0.9-9.8) %]
than the ovalbumin exposed animals (OVA group)
(p<0.001). Treatment with 1400 W diminished the NF-kB
expression in the sensitized animals (OVA-W group)
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Figure 2 “Box-plots” of the percentage of increase in tissue
resistance (Rt%) (A) and elastance (Et%) of the five
experimental groups (B). *p<0.001 compared to SAL, OVA-NOR,
OVA-W, and OVA-NOR-W groups.
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compared to the ovalbumin exposed ones (p<0.001). The
ovalbumin-exposed animals that received both 1400 W
and nor-NOHA (OVA-NOR-W group) showed a lower
expression of NF-kB in lung tissue than the OVA-W ani-
mals [4.2 (1.7-6.3) %] and [13.0 (11.1-14.1) %, respectively,
p<0.001]. However, there were no differences between the
OVA-NOR and OVA-NOR-W groups.
The association of iNOS and Arginase 2 inhibition
potentates the reduction of isoprostane PGF2α expression
We observed an increased expression of PGF2α (Figure 7)
in the alveolar septum of guinea pigs exposed to ovalbu-
min (OVA group) [9.4 (5.0-14.3) %] compared with those
exposed only to saline (SAL group) [3.5 (1.6-5.5) %], to
that ovalbumin-exposed animals that received nor-NOHA
(OVA-NOR group) [4.7 (2.2-7.1) %] to that ones that re-
ceived 1400 W (OVA-W group) [2.1 (0.0-4.8) %] and to
that ovalbumin-exposed animals that received 1400 W
and nor-NOHA (OVA-NOR-W group) [0.1 (0.0-0.2) %]
(p<0.001 for all comparisons). The ovalbumin-exposed
animals that received 1400 W (OVA-W) showed a lower
expression of PGF2α in the alveolar septum than the
OVA-NOR animals. There was a significant reduction
of PGF2α in the alveolar septum in the OVA-NOR-W
group compared to the SAL, OVA-NOR and OVA-W
groups (p<0.001).
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Figure 4 “Box-plots” of arginase 2 activity in the alveolar septa
of the five experimental groups. *p<0.05 compared to SAL,
OVA-NOR and OVA-NOR-W groups. There were no differences
between OVA and OVA-W groups.
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Figure 5 “Box-plots” of iNOS-positive cells in the alveolar septa
of the five experimental groups. *p<0.001 compared to the SAL,
OVA-NOR, and OVA-NOR-W groups. **p<0.001 compared to
OVA-NOR-W group.
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Figure 6 “Box-plots” of NF-kB expression (%) in the alveolar
septa of the five experimental groups. *p<0.05 compared to SAL,
OVA-NOR, OVA-W and OVA-NOR-W groups. **p<0.001 compared to
SAL, OVA-NOR and OVA-NOR-W groups.
SAL OVA
OVA
-NO
R
OVA
-W
OVA
-NO
R-W
A
rg
in
as
e 
2 
(%
)
0
10
20
30
40
50
* **
Figure 3 “Box-plots” of arginase 2 expression (%) in the
alveolar septa of the five experimental groups. *p<0.001
compared to SAL, OVA-NOR, OVA-W, and OVA-NOR-W groups.
**p<0.001 compared to OVA-NOR-W group.
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Correlation of arginase 2, Isoprostane PGF2α, iNOS, NF-kB
with distal lung mechanics
In order to better understand all the results and the
mechanisms involved, we also performed an analysis of
correlation among the functional parameters and the
histopathologycal findings. We observed a positive and
correlation between Rt with NF-kB expression (R=0.5
and p<0.002); with iNOS positive cells (R=0.762 and
p<0.001); Isoprostane PGF2α (R=0.375 and p<0.05) and
arginase 2 expression (R=0.569 and p<0.001) (Table 1). In
addition, we observed a positive and correlation between
NF-kB expression with iNOS positive cells (R=0.573 and
p<0.01) and arginase 2 expression (R=0.548 and p<0.01)
(Table 1).
Descriptive analysis
The control group (SAL group) showed low amounts of
arginase 2, iNOS positive cells, NF-kB and PGF2α content
in alveolar tissue sections, coincident with the mainten-
ance of the histoarchitecture of the alveolar septa. In
contrast, the distal lung parenchyma of OVA-exposed and
vehicle-treated animals showed an increase in iNOS
positive cells and in the amount of arginase, NF-kB and
PGF2α. The 1400 W and NOR-NOHA treatments in
ovalbumin-exposed animals (OVA-NOR-W group) re-
duced all these parameters below the amounts detected
in the OVA group. The association of both treatments
caused larger reductions than either treatment alone in
isoprostane PGF2α expression (Figure 8).
Discussion
Previously, we have already shown that the mainly cells
present in airway walls of this asthma model are eosino-
phils, CD4+ lymphocytes, iNOS and nNOS positive cells
[4,6,24,28]. In addition, we had demonstrated in distal
lung of this animal asthma model that eosinophil dens-
ity, iNOS positive cells and isoprostane PGF2α were in-
creased due to the effect of the sensitization process.
These histopathologycal alterations were correlated with
distal lung mechanics responses either after acethylcholine
or antigen challenge [2,3,28].
In the present study, we demonstrated that chronic
distal lung inflammation was associated with an increase
in arginase content and iNOS positive cells. These results
were associated with constriction of the distal lung paren-
chyma. Drazen, Schneider [33] showed that ultrathin
guinea-pig lung strips, which contained no conducting
airways or blood vessels, contracted after histamine or
carbachol challenge. These investigators concluded that
alveolar interstitial cells and/or alveolar duct smooth
muscle were responsible for the response. Although in the
present study the strips were represented by more than
90% alveolar walls (Table 2) it was not possible to exclude
a constrictor effect of some distal airways and vessels.
The increased iNOS expression leads to activation of
the oxidative stress pathway and formation of PGF2α,
which had a procontractile effect. In addition, we showed
that the mechanism involved in the activation of arginase
and the iNOS pathways may be related to the modulation
of NF-kB expression. Finally, we demonstrated that the as-
sociation of both inhibitors potentiated the reduction of
isoprostane PGF2α expression in this animal model.
The efficacy of these treatment protocols was dem-
onstrated by the significant reduction of the number of
iNOS-positive cells and arginase content in the lung
tissue of animals exposed to ovalbumin and treated
with 1400 W and nor-NOHA, respectively. We confirm
previous studies showing that 1400W has in vivo se-
lectivity for iNOS [24] and that nor-NOHA is a potent
and highly selective inhibitor of arginase [34]. In fact,
the nor-NOHA inhibition used is specific for arginase
2. Then the mechanism involved in the modulation of
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Figure 7 “Box-plots” of PGF2α expression (%) in the alveolar
septa of the five experimental groups. *p<0.001 compared to
SAL, OVA-NOR, OVA-W and OVA-NOR-W groups. **p<0.001
compared to OVA-NOR group. #p<0.001 compared to SAL
and OVA-NOR.
Table 1 Spearman correlation: arginase 2, Isoprostane
PGF2α, iNOS, NF-kB, %Et and %Rt
Isoprostane iNOS NF-kB %Rt %Et
Arginase 2 R 0.508 0.519 0.548 0.569 0.0847
p 0.00367 0.00293 0.00150 0.000909 0.648
Isoprostane
PGF2α
R 0.121 0.365 0.375 0.0434
p 0.512 0.0433 0.0379 0.814
iNOS R 0.573 0.762 0.220
p 0.000810 0.000000200 0.232
NF-kB R 0.533 0.443
p 0.00216 0.0129
R = Correlation Coefficient.
p = Value.
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iNOS pathway by arginase is not related to nor-NOHA
competition.
Considering the mechanisms involved in an allergic
inflammatory microenvironment pro-inflammatory cyto-
kines, like IL-4, IL-1β, and tumour necrosis factor α
(TNF-α) and oxidative stress might upregulate the pro-
duction of iNOS-derived NO through activation of
transcription factors, such as signal transcription 1
(STAT1), STAT6 and nuclear factor kB (NF-kB) [35]. In
our study, arginase 2 blockade leads to decreased
NF-KB expression. The treatment with nor-NOHA also
leads to a reduction of iNOS expression. This effect
could be explained by the fact that iNOS expression is
NF-KB dependent.
C DBA
HGFE
LKJI
PONM
TSRQ
Figure 8 Guinea pig lung tissue samples obtained from controls (panels A, B, C and D), OVA-exposed and vehicle-treated animals
(panels E, F, G and H), OVA-exposed and nor-NOHA treated animals (panels I, J, K and L), OVA-exposed and 1400 W treated animals
(panels M, N, O and P), and OVA-exposed and nor-NOHA and 1400 W treated animals (panels Q, R, S and T). Immunohistochemistry
analysis for arginase (panels A, E, I, M and Q - ×400), iNOS positive cells (panels B, F, J, N and R - ×1000), NF-kB (panels C, G, K, O and S – ×400),
and PGF2α (panels D, H, L, P and T - ×400). The control group showed low amounts of iNOS positive cells, NF-kB, arginase and PGF2α in alveolar
tissue sections. In contrast, the distal lung parenchyma of OVA-exposed and vehicle-treated animals showed an increase in the amount of
arginase, iNOS-positive cells, NF-kB and PGF2α. The 1400 W and nor-NOR treatments in ovalbumin-exposed animals reduced all these parameters
compared to the OVA group. Both treatments in conjunction contributed to a greater PGF2α reduction.
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However, we observed differences in the intensity of the
effects of 1400 W and nor-NOHA on the number of iNOS
positive cells. We considered that it may be dependent on
the doses and / or the differences between the protocols of
treatments used.
It is noteworthy that, we demonstrated for the first
time in an animal model of chronic allergic inflamma-
tion, an increase in arginase 2 expression in distal lung
parenchyma. A number of studies have reported an in-
crease in arginase activity in the airways of both acute and
chronic guinea pig models of allergic asthma [18,20].
Increased arginase 2 activity and/or expression have also
been demonstrated in other animal models using different
antigens, species and strains [36].
Some studies also hypothesized that endogenous argi-
nase activity could affect both the proximal and distal
airways. Using a perfused guinea pig tracheal tube prep-
aration, Meurs et al. [18] demonstrated that the potent
and highly specific arginase inhibitor nω-hydroxy-nor-l
arginine (nor-NOHA) caused a concentration-dependent
inhibition of methacholine-induced airway constriction,
which was reversed by L-NAME. This result shows that
arginase activity in the airways is also involved in the
modulation of airway responsiveness by limiting cNOS-
derived bronchodilating NO production.
Maarsingh et al. [37] showed that in sensitized animals
there was an increase in arginase activity, which was
completely prevented by the administration of ABH (an
arginase inhibitor). So do we, using a different arginase
inhibitor (nor-NOHA). Nonetheless, Maarsingh et al. [37]
evaluated the proximal airways while our study was
performed in the distal lung parenchyma.
Using a guinea-pig model of allergic asthma, De Boer
et al. [38] investigated the role of nitric oxide in allergen
induced airway hyperresponsiveness after the early
asthmatic reaction by examining the effects of the NO
synthase inhibitor L-NAME on the responsiveness to
methacholine and histamine of isolated perfused tracheae
from unchallenged and sensitized animals. The authors
also demonstrated that a NO deficiency contributes to
allergen-induced airway hyperresponsiveness after the
early airway responsiveness.
In asthmatic airways, the expression of iNOS is mark-
edly increased by proinflammatory cytokines such as
TNF-α and IFN-ɣ in inflammatory cells and in the airway
epithelium [39,40]. Prado et al. [7] also found a reduction
in iNOS and nNOS positive cells after treatment with this
specific iNOS inhibitor (1400 W) and L-NAME, respect-
ively. Few authors, however, have assessed the effects of
inhibition of nitric oxide synthases in modulating the in-
flammatory and functional responses that occur in the lung
parenchyma in the chronic inflammatory response.
In this regard, Angeli et al. [3] analyzed the oscillatory
mechanical responses of distal lung tissue in guinea pigs
with chronic pulmonary inflammation. The authors ob-
served that sensitized animals treated with L-NAME had
a reduction in both lung tissue resistance and elastance
after antigen challenge. Starling et al. [2], assessing the
distal lung functional changes induced by chronic inflam-
mation, found that treatment with 1400 W decreased the
response of both elastance and resistance in animals ex-
posed to ovalbumin. In conjunction, these studies showed
that nitric oxide contributes to the constriction of the pul-
monary parenchyma in this experimental model.
Considering that L-arginine is the common substrate
for both nitric oxide synthases and for the arginase en-
zyme, it is possible that blocking one of these enzymatic
pathways could affect the other one through competition
for the same substrate [20,22]. These enzymes convert
L-arginine into L-ornithine and urea and are the key en-
zymes of the urea cycle in the liver (arginase 1) but are
also expressed in cells and tissues that lack a complete
urea cycle, e.g., arginase 2 expression in the lung [21].
Arginases are involved in cell growth and tissue repair
via the increased production of L-ornithine, a precursor
of polyamines and proline [21].
Que et al. [41] demonstrated the expression of arginase
in the bronchial epithelium and in peribronchial connect-
ive tissue fibroblasts. In addition, Meurs et al. [22] showed
that arginase appears to modulate the tone of the airway
smooth muscle and potentiates methacholine-induced air-
way constriction. Arginase accomplishes these actions by
forcing the common substrate L-arginine away from epi-
thelial cNOS to diminish the agonist induced production
of NO. Arginases and NOS compete for the bioavailability
of the same substrate, L-arginine, and are involved indir-
ectly in the regulation of NO synthesis [18,21].
Corroborating this idea, Morris et al. [42] showed that
there is a reduction in the levels of plasma arginine in
asthmatic patients compared with patients without
asthma but with increased serum arginase activity. To-
gether, these results suggest that increased arginase
activity in asthma may be a contributing factor to the
decrease in the circulating levels of Larginine and the
Table 2 Morphometric determination of distal
proportions of alveolar septa, airways, and vessels
Groups % of alveolar septa % of vessels % of airways
SAL 90.7 (90.3-90.9) 9.3 (8.7-10.7) 0.8 (0.6-2.0)
OVA 90.3 (89.6-91.4) 8.6 (7.6-9.1) 1.1 (0.9-1.4)
OVA-NOR 91.5 (92.5-91.5) 7.1 (5.7-7.7) 0.6 (0.4-0.8)
OVA-W 90.2 (90.1-90.4) 10.1 (9.4-10.6) 0.7 (0.4-1.2)
OVA-N0R-W 93.1 (90.1-93.8) 5.6 (6.4-5.7) 0.4 (0.6-0.4)
There were no significant differences between the proportions of alveolar
septa, airways, and vessels among the five experimental groups.
Median (25-75%).
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consequent NO deficiency. Thus, blocking NO produc-
tion could be a tool to study the indirect involvement of
arginase in various pathophysiological processes [22,43].
Several powerful drugs have been used to investigate
the role of arginases in the pathophysiology of asthma,
including nor-NOHA (Nω-hydroxy-nor-L-arginine), which
is one of the most potent inhibitors of arginase [21]. Meurs
et al. [22], studying in vitro tracheal ring-sensitized guinea
pigs, demonstrated that treatment with nor-NOHA re-
duced the hyperresponsiveness to methacholine, and this
effect was reversed by treatment with L-NAME.
In the present study, we evaluated the effects of
arginase 2 inhibition on functional alterations of distal
lung parenchyma. We demonstrated that nor-NOHA de-
creased both the maximal increase in tissue resistance and
elastance after ovalbumin challenge in sensitized animals,
suggesting that arginase 2 contributes to the modulation
of lung parenchyma specific hyperresponsiveness in this
experimental model.
One possible explanation for these results may be re-
lated to a decrease in the production of bronchodilating
NO, presumably through competition with cNOS for the
common substrate, L-arginine, as previously shown in
other studies discussed above [18]. In the lungs, the con-
stitutive NOS (cNOS) isozymes are mainly expressed in
endothelial cells (eNOS), in inhibitory non-adrenergic
noncholinergic nerves (nNOS), and epithelial cells (nNOS
and eNOS) [38]. However, in the present study we did not
evaluate the expression of constitutive nitric oxide en-
zymes to confirm this possibility.
Interestingly, the animals that were also treated with
nor-NOHA showed a lower amount of iNOS positive
cells in lung tissue. Our hypothesis is that during the
period of the experiment in which the distal lung slices
were in contact with nor-NOHA, there was a decrease
in NF-kB expression with a subsequent decrease in both
arginase 2 and iNOS expression.
To test this hypothesis we evaluated the expression of
NF-kB in distal lung tissue from the five experimental
groups. We demonstrated that both treatments with
1400 W and NOR-NOHA diminished the NF-kB expres-
sion in sensitized animals. However, the association of
1400 W and nor-NOHA did not modify this response in
sensitized animals. In this sense, Ckless et al. [14] also
showed that inhibition or knockdown of arginase caused
a small but consistent attenuation of basal and TNF-α
stimulated NF-kB transcriptional activity. We also used
a specific iNOS inhibitor (1400 W). In addition, we pre-
viously had shown that L-NAME effects were mostly
due to constitutive NOS blockade and different forms
specific of iNOS inhibitions [6].
NF-kB is an essential transcription factor not only for
the induction of iNOS, but also for the up-regulation of
CAT-2B. The simultaneous up-regulation of CAT-2B
with iNOS is considered as a mechanism to ensure a high
substrate supply for iNOS. Hammermann et al. (2000)
[44] clearly showed that these results were evaluated after
20 hs of culture contact with L-arginine. In addition, we
clarified that in the present study. The animals received
1400 W (iNOS inhibitor) daily during 72 hs before the
experiment. Then, this time was sufficient to inhibit
NF-KB expression.
We also showed that there was a reduction of 8-
isoprostane expression in animals exposed to ovalbumin
that received either nor-NOHA or 1400 W treatment.
Ogino et al. [45] showed that arginase 1 protein expres-
sion in blood serum has recently been associated with
PGF2α in healthy Japanese people and may become a new
biomarker for the early prediction of oxidative stress-
related diseases. These findings also corroborate the idea
that not only iNOS but also arginase activation increases
activation of the oxidative stress pathway. As previously
shown, this may have detrimental effects on lung tissue
structure [2,3].
Another point to be analyzed is that the association of
both inhibitors caused larger reductions than either
treatment alone in isoprostane PGF2α expression. This
was sufficient to reduce PGF2α but did not affect the
distal lung mechanical responses. Considering the import-
ance of isoprostanes as contractile agents, we expected
that there was a more prominent effect on lung mechanics
in animals that received the two inhibitors. In addition, De
Boer et al. [46] showed that the increased formation of the
highly reactive procontractile and proinflammatory oxi-
dant peroxynitrite plays an important role in airway
hyperresponsiveness after the late airway responsiveness.
It is possible that differences in the protocols of treatment
with these inhibitors and/or different doses may contrib-
ute to attenuate the mechanical responses observed. How-
ever, this needs to be tested in another study.
Reinforcing the previous results, we showed that the
resistance of the distal lung was correlated with the
number of iNOS positive cells, isoprostane PGF2α and
NF-kB expression [28,47]. In the present study we also
showed that arginase 2 was correlated to resistance of dis-
tal lung tissue. Another point is that the NF-kB expression
was correlated to arginase 2 expression and the number of
iNOS positive cells. These results suggested a mechanistic
pathway that needs to be further investigated.
Although we had previously mentioned some limita-
tions of the present study, we also note that the results
obtained in animal models may not be always applicable
in humans. Nevertheless, it is important to remember
that the guinea pig model is one of the best animal
models to study asthma, as its lung anatomy is similar to
humans, and it mimics some of the characteristics of
human asthma such as the eosinophilic inflammatory
and remodeling process [4,48]. Another point is that we
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evaluated the distal lung parenchyma. In fact, more
studies need to be performed using chronic treatment
with arginase inhibitors in intact animals. In the present
study, the main limitation for performing this systemic
treatment is the high cost of the drug. Finally, we also
need to evaluate not only the expression of iNOS but
also the activity of this enzyme, as well as the evaluation
of constitutive nitric oxide sintase isoforms.
Conclusions
In conclusion, this present study demonstrated that in-
creased arginase 2 expression and activity contributes to
increased iNOS expression and for the constriction of
the distal lung parenchyma, likely due to altered NF-kB
expression. These alterations associated with high PGF2α
expression. Treatment with iNOS and arginase specific
inhibitors reduced 8-isoprostane expression. The modula-
tion of these pro-inflammatory pathways may represent
future pharmacological tools for controlling pulmonary
functional alterations induced by chronic inflammation.
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